Clinical Trial Update: Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT [Phase 1]

View source ↗

Summary

This is an active Phase 1 clinical trial evaluating Gamma Delta T-cell Infusion for Acute Myeloid Leukemia at high risk of relapse after allogeneic HCT. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gamma delta T-cell infusion (gamma-delta T-cell therapy)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING